<DOC>
	<DOCNO>NCT02162251</DOCNO>
	<brief_summary>To investigate safety effectiveness administration donepezil hydrochloride menatine hydrochloride patient Alzheimer 's Disease clinical practice .</brief_summary>
	<brief_title>Post-marketing Surveillance Donepezil Hydrochloride Investigation Safety Effectiveness Combination Therapy Donepezil Hydrochloride Memantine Hydrochloride Patients With Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Inclusion criterion : Patients diagnose Alzheimer 's Disease administer donepezil hydrochloride memantine hydrochloride clinical practice . Exclusion criterion : Patients history hypersensitivity ingredient Aricept piperidine derivative .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>donepezil hydrochloride</keyword>
</DOC>